SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

The FDA's issuance of a Complete Response Letter (CRL) for Regenxbio's RGX-121 gene therapy for Hunter syndrome is driving intense conversation, with the community expressing significant concerns about the trial design, financial implications, and potential dilution amidst broader scrutiny of gene therapy development.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid anticipation for its upcoming earnings and significant market speculation regarding the uncertain fate of a House-passed bill to extend ACA subsidies; the community remains sharply divided, with some foreseeing a major re-rating due to policy tailwinds and execution, while others highlight financial challenges and broader sector headwinds.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is generating significant buzz following its Nasdaq listing, a recent financing round, and a reverse stock split, sparking an active community debate on the revolutionary potential of its SAT-3247 drug for Duchenne muscular dystrophy against concerns regarding dilution and the early stage of its clinical development.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals is trending due to a blowout quarterly earnings report that exceeded estimates, with the community actively discussing its perceived undervaluation and anticipating a significant price surge, bolstered by strong precious metals market conditions.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog (DDOG) is trending amidst high anticipation for its upcoming earnings report, with the community debating its strong position as an AI beneficiary and observability leader against concerns over competitive pressures and a broader software sector valuation reset.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief...

Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday...

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced...

Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital

D Boral Capital upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research report on Monday...

Turn Therapeutics (NASDAQ:TTRX) Coverage Initiated at D. Boral Capital

D. Boral Capital assumed coverage on Turn Therapeutics in a research report on Monday. They set a "buy" rating and a $8.00 price target on the stock...

Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was...

Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden acquired 20,532 shares of Turn Therapeutics stock in a transaction dated Friday, November 21st. The shares were bought at...

Turn Therapeutics (NASDAQ:TTRX) Releases Quarterly Earnings Results

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter...

Shares of Turn Therapeutics&nbsp;surged over 370% in early premarket trade on Thursday,&nbsp;extending&nbsp;gains&nbsp;from the after-hours session on the Nasdaq Capital Market after the California-based biotech made its public listing on Wednesday.&nbsp;The U.S. Securities and Exchange Commission had declared Turn’s registration statement effective on Sept. 30, clearing the way for the IPO.<a href="https://stocktwits.com/symbol/TTRX">Turn Therapeutics’ stock</a> surged 134% to $9.40 in extended trading on Wednesday, placing it among the top after-hours gainers on the day.Founder and CEO Bradley Burnham said during the Nasdaq closing bell ceremony that the company was “built on a shoestring, with an absolute disdain for waste,” highlighting its lean approach to research and operations.&nbsp;Turn Therapeutics develops and commercializes next-generation products for dermatology, wound care, and infectious diseases, with three FDA-cleared medical devices and late-stage clinical programs in eczema and onychomycosis.&nbsp;Its proprietary formula targets inflammatory cytokines such as IL-36a, IL-36y, IL-4, and IL-31, and has been confirmed as non-cytotoxic and non-sensitizing.&nbsp;The company also develops formulations that are 99.9% effective against Methicillin-Resistant Staphylococcus aureus, a type of bacteria that’s resistant to many commonly used antibiotics, and qualify for the FDA’s Qualified Infectious Disease Product (QIDP) program.Turn has also developed its Permafusion platform, which allows pharmaceutical ingredients to penetrate deeper skin and tissue layers without emulsifiers, improving bioavailability and minimizing side effects.&nbsp;Beyond dermatology and wound care, Turn is developing thermostable vaccine delivery technology to expand access to essential medicines in underserved global markets.The company’s financial advisor for the listing was Clear Street LLC, with legal counsel provided by Davis Polk &amp; Wardwell LLP.&nbsp;On Stocktwits, retail sentiment was ‘neutral’ amid ‘extremely low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Turn Therapeutics’ stock (TTRX) surged 134% to $9.40 in extended trading on Wednesday, placing it among the top after-hours gainers on the day. (Representative Image: Getty Images)

Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?

The stock’s debut on Wednesday followed the SEC’s approval of its registration statement on Sept. 30, clearing the way for its public listing as it advances late-stage clinical programs in eczema and onychomycosis.

Equity

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded on January 6, 2015 and is headquartered in Westlake Village, CA.

Turn Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

TTRX
Turn Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TTRX News

TTRXTurn Therapeutics Inc